Chemomab Therapeutics
CMMB
5 hedge funds and large institutions have $346K invested in Chemomab Therapeutics in 2020 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 4 closing their positions.
0.02% less ownership
Funds ownership: 0.03% → 0.01% (-0.02%)
17% less funds holding
Funds holding: 6 → 5 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
55% less capital invested
Capital invested by funds: $763K → $346K (-$417K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$129K |
| 2 |
VF
Virtu Financial
New York
|
+$85.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$18.3K |
| 4 |
Morgan Stanley
New York
|
+$12.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Palisade Capital Management
Fort Lee,
New Jersey
|
-$421K |
| 2 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$267K |
| 3 |
PF
Phoenix Financial
Givatayim,
Israel
|
-$28K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $148K | +$129K | +1,336 | New |
|
|
VF
2
Virtu Financial
New York
| $120K | +$85.1K | +883 | +431% |
|
|
RC
3
RegentAtlantic Capital
Morristown,
New Jersey
| $43K | – | – | – |
|
|
4
Citadel Advisors
Miami,
Florida
| $21K | +$18.3K | +190 | New |
|
|
5
Morgan Stanley
New York
| $14K | +$12.2K | +127 | New |
|
|
PCM
6
Palisade Capital Management
Fort Lee,
New Jersey
| – | -$421K | -5,776 | Closed |
|
|
MIH
7
Meitav Investment House
Bene-Beraq,
Israel
| – | -$267K | -3,663 | Closed |
|
|
PF
8
Phoenix Financial
Givatayim,
Israel
| – | -$28K | -408 | Closed |
|
|
9
Osaic Holdings
Scottsdale,
Arizona
| – | -$3K | -37 | Closed |
|
CMMB Hedge Fund Activity: Q4 2020 in Review
5 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q4 2020, worth a combined $346K — down 55% from $763K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CMMB and 3 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $129K. The largest seller was Palisade Capital Management, exiting entirely with an estimated $421K sold.
- 5 institutional investors held Chemomab Therapeutics (CMMB) as of Q4 2020, down from 6 in Q3 2020.
- Funds reported $346K of Chemomab Therapeutics stock for Q4 2020, down 55% quarter-over-quarter.
- 3 funds opened new Chemomab Therapeutics positions in Q4 2020 and 4 closed out, a net change of -1 holder.
- The largest Chemomab Therapeutics buyer in Q4 2020 was Renaissance Technologies, an estimated $129K added.
- The largest Chemomab Therapeutics seller in Q4 2020 was Palisade Capital Management, an estimated $421K sold.
Based on aggregated 13F filings for Q4 2020.